Insmed's Diabetes patent is still valid in the eleven European countries listed below. Insmed paid nine of the eleven annual renewal fees as recently as six months ago.
The patent in question, EP1183042, covers the use of iPlex as a therapy for Diabetes. Why would Insmed still be paying renewal fees to protect the use of a drug you tell us is dead?
"... besides it encourages the nonuthins who haven't accepted Iplex is shelved for 4 ++ years!,.... a term in biospeak that means dead ..."
Btw - what does the term "nonuthin" mean in biospeak?
Thanks for that, Fud. Could you tell us where we can see the information about the renewals?
I googled "EP1183042" and it was a fun read with some good recollections of time past. If some new people go back to read here is some help to get you to understand the import of what Fud is saying:
---Celtrix.....forerunner to Insmed
---SomatoKine......previous name of iPlex
---Andreas Sommer........perhaps Zake can fill this in.
In fact, Zake, can you give some history of the information above?